nach oben

Medical Oncology

Erschienen in:

01.06.2021 | Review Article

PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer

verfasst von: Devashish Desai, Pushti Khandwala, Meghana Parsi, Rashmika Potdar

Erschienen in: Medical Oncology | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Pancreatic cancer, being one of the most fatal cancers, is the 7th leading cause of death globally. Cancer that is resistant to current treatment proves that there is a need for personalized and targeted therapy, based on the tumor and genomic markers. Pembrolizumab and Larotrectinib are examples of current medications used as targeted therapy in pancreatic cancer. Pancreatic cancer has many different molecular subgroups, providing the opportunity for the development of new drugs that can target these groups. Poly (ADP-Ribose) polymerase inhibitors (PARPi) are a group of drugs inhibiting PARP to decrease the stability of the cancer cells. Currently, PARPi are mostly used in ovarian and breast cancer. There are multiple studies that have shown positive effects of PARPi in decreasing the tumor burden in advanced pancreatic cancer. PARPi are the future of pancreatic cancer management, and hence it is important to understand their mechanism, resistance pathways, and their application in the real world.

F Bray J Ferlay I Soerjomataram RL Siegel LA Torre A Jemal 2018 Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 68 6 394 424PubMed

Ferlay JEM, Lam F, Colombet M, Mery L, Pineros M, Znaor A, Soerjomataram I, Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer; Available from https://gco.iarc.fr/today, Accessed 05 October 2018.

W Wu X He L Yang Q Wang X Bian J Ye Y Li L Li 2018 Rising trends in pancreatic cancer incidence and mortality in 2000–2014 Clin Epidemiol. 10 789 797PubMedPubMedCentral

Ferlay J EM, Lam F, Colombet M, Mery L, Pineros M, Znaor A, Soerjomataram I, Global cancer observatory: cancer tomorrow. Lyon, France: International Agency for Research on Cancer; Accessed 07 October 2018. Available from: http://gco.iarc.fr/tomorrow/graphic-isotype?

P Rawla T Sunkara V Gaduputi 2019 Epidemiology of pancreatic cancer: global trends, etiology, and risk factors World J Oncol. 10 1 10 27 https://doi.org/10.14740/wjon1166CrossRefPubMedPubMedCentral

A McGuigan P Kelly RC Turkington C Jones HG Coleman RS McCain 2018 Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment, and outcomes World J Gastroenterol. 24 43 4846 4861 https://doi.org/10.3748/wjg.v24.i43.4846CrossRefPubMedPubMedCentral

Pancreatic Cancer: Types of Treatment Approved by the Cancer.Net Editorial Board, 05/2020 https://www.cancer.net/cancer-types/pancreatic-cancer/types-treatment#:~:text=The%20current%20treatment%20options%20for,important%20part%20of%20cancer%20care.

Siegel RL, Miller KD, Jemal A; Cancer Statistics, 2017. CA Cancer J Clin. 2017 Jan; 67(1):7–30. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014 Jun 1; 74(11):2913–21.

M Hidalgo 2010 Pancreatic cancer N Engl J Med 362 1605 1617PubMed

10.

LA Chantrill AM Nagrial C Watson AL Johns M Martyn-Smith S Simpson 2015 Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial Clin Cancer Res. 21 2029 2037PubMed

11.

Research C for DE and FDA Grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. FDA. Accessed on 17 August 2019

12.

Research C for DE and FDA Approves Larotrectinib for Solid Tumors with NTRK Gene Fusions. FDA. Accessed on 17 August 2019. Available online: http://www.fda.gov/drugs/fda-approves-larotrectinib-solid-tumors-ntrk-gene-fusions-0

13.

G Lal G Liu B Schmocker P Kaurah H Ozcelik SA Narod M Redston S Gallinger 2000 Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations Can Res. 60 409 416

14.

NJ Roberts Y Jiao J Yu L Kopelovich GM Petersen ML Bondy 2012 ATM mutations in patients with hereditary pancreatic cancer Cancer Discov. 2 41 46PubMed

15.

S Jones RH Hruban M Kamiyama M Borges X Zhang DW Parsons JCH Lin E Palmisano K Brune EM Jaffee 2009 Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene Science 324 217PubMedPubMedCentral

16.

N Resta D Pierannunzio GM Lenato A Stella R Capocaccia R Bagnulo 2013 Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: results of an Italian multicenter study Dig Liver Dis. 45 606 611PubMed

17.

AK Win JP Young NM Lindor KM Tucker DJ Ahnen GP Young 2012 Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study J Clin Oncol. 30 958 964PubMedPubMedCentral

18.

S Jones RH Hruban M Kamiyama M Borges X Zhang DW Parsons JC Lin E Palmisano K Brune EM Jaffee 2009 Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene Science 324 e217 https://doi.org/10.1126/science.1171202CrossRef

19.

RR McWilliams ED Wieben KG Rabe KS Pedersen Y Wu H Sicotte GM Petersen 2011 Prevalence of CDKN2A mutations in pancreatic cancer patients: Implications for genetic counseling Eur J Hum Genet. 19 472 478 https://doi.org/10.1038/ejhg.2010.198CrossRefPubMed

20.

GH Su RH Hruban RK Bansal GS Bova DJ Tang MC Shekher AM Westerman MM Entius M Goggins CJ Yeo 1999 Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers Am J Pathol. 154 1835 1840 https://doi.org/10.1016/S0002-9440(10)65440-5CrossRefPubMedPubMedCentral

21.

AC Tersmette GM Petersen GJ Offerhaus FC Falatko KA Brune M Goggins E Rozenblum RE Wilentz CJ Yeo JL Cameron 2001 Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer Clin Cancer Res. 7 738 744PubMed

22.

S Holter A Borgida A Dodd R Grant K Semotiuk D Hedley N Dhani S Narod M Akbari M Moore 2015 Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma J Clin Oncol. 33 3124 3129 https://doi.org/10.1200/JCO.2014.59.7401CrossRefPubMed

23.

SA Hahn B Greenhalf I Ellis M Sina-Frey H Rieder B Korte B Gerdes R Kress A Ziegler JA Raeburn 2003 BRCA2 germline mutations in familial pancreatic carcinoma J Natl Cancer Inst. 95 214 221PubMed

24.

N Waddell M Pajic AM Patch DK Chang KS Kassahn P Bailey AL Johns D Miller K Nones K Quek 2015 Whole genomes redefine the mutational landscape of pancreatic cancer Nature 518 495 501 https://doi.org/10.1038/nature14169CrossRefPubMedPubMedCentral

25.

D Hanahan RA Weinberg 2011 Hallmarks of cancer: the next generation Cell 144 646 674

26.

MF Langelier T Eisemann AA Riccio JM Pascal 2018 ARP family enzymes: regulation and catalysis of the poly(ADP-ribose) post translational modification Curr Opin Struct Biol. 53 187 198PubMedPubMedCentral

27.

TA Hopkins Y Shi LE Rodriguez LR Solomon CK Donawho EL DiGiammarino SC Panchal JL Wilsbacher W Gao AM Olson DF Stolarik DJ Osterling EF Johnson D Maag 2015 Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors Mol Cancer Res. 13 11 1465 1477PubMed

28.

J Murai SY Huang BB Das A Renaud Y Zhang JH Doroshow J Ji S Takeda Y Pommier 2012 Trapping of PARP1 and PARP2 by clinical PARP inhibitors Cancer Res. 72 21 5588 5599PubMedPubMedCentral

29.

KJ Rimar PT Tran RS Matulewicz M Hussain JJ Meeks 2017 Jun The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies Cancer 123 11 1912 1924 https://doi.org/10.1002/cncr.30631CrossRefPubMedPubMedCentral

30.

J Mateo CJ Lord V Serra 2019 A decade of clinical development of PARP inhibitors in perspective Ann Oncol. 30 9 1437 1447 https://doi.org/10.1093/annonc/mdz192CrossRefPubMedPubMedCentral

31.

P Francica S Rottenberg 2018 Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response Genome Med. 10 1 101 https://doi.org/10.1186/s13073-018-0612-8CrossRefPubMedPubMedCentral

32.

CR Calabrese R Almassy S Barton MA Batey AH Calvert S Canan-Koch BW Durkacz Z Hostomsky RA Kumpf S Kyle J Li K Maegley DR Newell E Notarianni IJ Stratford D Skalitzky HD Thomas LZ Wang SE Webber KJ Williams NJ Curtin 2004 Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361 J Natl Cancer Inst. 96 1 56 67PubMed

33.

MJ Schiewer JF Goodwin S Han 2012 Dual roles of PARP-1 promote cancer growth and progression Cancer Discov. 2 12 1134 1149 https://doi.org/10.1158/2159-8290.CD-12-0120CrossRefPubMedPubMedCentral

34.

LJ Barber S Sandhu L Chen 2013 Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor J Pathol. 229 3 422 429PubMed

35.

B Norquist KA Wurz CC Pennil R Garcia J Gross W Sakai 2011 Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas J Clin Oncol. 29 3008 3015PubMedPubMedCentral

36.

P Brugge Ter P Kristel E Burg van der 2016 Mechanisms of therapy resistance in patient-derived xenograft models of BRCA1-deficient breast cancer J Natl Cancer Inst. https://doi.org/10.1093/jnci/djw148CrossRefPubMed

37.

YE Choi K Meghani ME Brault L Leclerc YJ He TA Day 2016 Platinum and PARP inhibitor resistance due to overexpression of MicroRNA-622 in BRCA1-mutant ovarian cancer Cell Rep. 14 429 439PubMedPubMedCentral

38.

J Nacson JJ Krais AJ Bernhardy 2018 BRCA1 mutation-specific responses to 53BP1 loss-induced homologous recombination and PARP inhibitor resistance Cell Rep. 25 5 1384PubMedPubMedCentral

39.

H Dungrawala 2017 RADX promotes genome stability and modulates chemosensitivity by regulating RAD51 at replication forks Mol Cell. 67 e375 374 386PubMedPubMedCentral

40.

SA Yazinski V Comaills R Buisson MM Genois HD Nguyen CK Ho 2017 ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells Genes Dev. 31 318 332PubMedPubMedCentral

41.

A Ray Chaudhuri E Callen X Ding E Gogola AA Duarte JE Lee 2016 Replication fork stability confers chemoresistance in BRCA-deficient cells Nature 535 382 387PubMed

42.

J Murai SW Tang E Leo SA Baechler CE Redon H Zhang 2018 SLFN11 blocks stressed replication forks independently of ATR Mol Cell. 69 371–84 e376

43.

G Minckwitz von BM Muller S Loibl J Budczies C Hanusch S Darb-Esfahani 2011 Cytoplasmic poly (adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy J Clin Oncol. 29 2150 2157

44.

AD D'Andrea 2018 Mechanisms of PARP inhibitor sensitivity and resistance DNA Repair (Amst). 71 172 176PubMed

45.

M Javle NJ Curtin 2011 The role of PARP in DNA repair and its therapeutic exploitation Br J Cancer. 105 1114 1122PubMedPubMedCentral

46.

A Vaidyanathan L Sawers AL Gannon P Chakravarty AL Scott SE Bray 2016 ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells Br J Cancer. 115 431 441PubMedPubMedCentral

47.

M Patel S Nowsheen S Maraboyina F Xia 2020 The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review Cell Biosci. 10 35 https://doi.org/10.1186/s13578-020-00390-7CrossRefPubMedPubMedCentral

48.

ClinicalTrials.gov: https://clinicaltrials.gov/ct2/results?term=PARP&Search=Apply&recrs=a&recrs=f&recrs=d&age_v=&gndr=&type=Intr&rslt

49.

ClinicalTrials.gov: https://clinicaltrials.gov/ct2/results?term=PARP&Search=Apply&recrs=e&age_v=&gndr=&type=Intr&rslt

50.

B Kaufman R Shapira-Frommer RK Schmutzler MW Audeh M Friedlander J Balmana G Mitchell G Fried SM Stemmer A Hubert 2015 Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation J Clin Oncol. 33 244 250 https://doi.org/10.1200/JCO.2014.56.2728CrossRefPubMed

51.

E Pujade-Lauraine JA Ledermann F Selle V Gebski RT Penson AM Oza J Korach T Huzarski A Poveda S Pignata 2017 Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial Lancet Oncol. 18 1274 1284 https://doi.org/10.1016/S1470-2045(17)30469-2CrossRefPubMed

52.

K Moore N Colombo G Scambia BG Kim A Oaknin M Friedlander A Lisyanskaya A Floquet A Leary GS Sonke 2018 Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer N Engl J Med. 379 2495 2505 https://doi.org/10.1056/NEJMoa1810858CrossRefPubMed

53.

M Robson SA Im E Senkus B Xu SM Domchek N Masuda S Delaloge W Li N Tung A Armstrong 2017 Olaparib for metastatic breast cancer in patients with a germline BRCA mutation N Engl J Med. 377 523 533 https://doi.org/10.1056/NEJMoa1706450CrossRefPubMed

54.

MR Mirza BJ Monk J Herrstedt AM Oza S Mahner A Redondo M Fabbro JA Ledermann D Lorusso I Vergote 2016 Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer N Engl J Med 375 2154 2164 https://doi.org/10.1056/NEJMoa1611310CrossRefPubMed

55.

R Kristeleit GI Shapiro HA Burris AM Oza P LoRusso MR Patel SM Domchek J Balmana Y Drew LM Chen 2017 A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors Clin Cancer Res. 23 4095 4106 https://doi.org/10.1158/1078-0432.CCR-16-2796CrossRefPubMed

56.

RL Coleman AM Oza D Lorusso 2017 Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet 390 1949 1961 https://doi.org/10.1016/S0140-6736(17)32440-6CrossRefPubMedPubMedCentral

57.

JK Litton HS Rugo J Ettl SA Hurvitz A Goncalves KH Lee L Fehrenbacher R Yerushalmi LA Mina M Martin 2018 Talazoparib in patients with advanced breast cancer and a germline BRCA mutation N Engl J Med. 379 753 763 https://doi.org/10.1056/NEJMoa1802905CrossRefPubMed

58.

M Gupta R Iyer C Fountzilas 2019 Poly(ADP-Ribose) polymerase inhibitors in pancreatic cancer: a new treatment paradigms and future implications Cancers (Basel). https://doi.org/10.3390/cancers11121980CrossRefPubMedPubMedCentral

59.

T Golan P Hammel 2019 Maintenance Olaparib for Germline BRCA-mutated metastatic pancreatic cancer N Engl J Med. 381 317 327 https://doi.org/10.1056/NEJMoa1903387CrossRefPubMedPubMedCentral

60.

J Rivero del EC Kohn 2017 PARP inhibitors: the cornerstone of DNA repair-targeted therapies Oncology (Williston Park) 31 4 65 273

61.

https://clinicaltrials.gov/

62.

M Yarchoan MC Myzak BA Johnson 3rd A Jesus-Acosta De DT Le EM Jaffee NS Azad RC Donehower L Zheng PE Oberstein RL Fine DA Laheru M Goggins 2017 Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer Oncotarget 8 27 44073 44081PubMedPubMedCentral

63.

J Bendell EM O’Reilly MR Middleton I Chau H Hochster A Fielding W Burke H Burris 2015 Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer Ann Oncol 26 4 804 811PubMed

64.

R Tuli SL Shiao N Nissen M Tighiouart S Kim A Osipov M Bryant L Ristow V Placencio-Hickok D Hoffman S Rokhsar K Scher SJ Klempner P Noe MJ Davis A Wachsman S Lo L Jamil H Sandler S Piantadosi A Hendifar 2019 A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer EBioMedicine 40 375 381 https://doi.org/10.1016/j.ebiom.2018.12.060CrossRefPubMedPubMedCentral

65.

MJ Pishvaian H Wang T Zhuang AR He JJ Hwang A Hankin L Ley K White SJ Littman LM Weiner J Marshall JR Brody 2013 A phase I/II study of ABT-888 in combination with 5-fluorouracil (5-FU) and oxaliplatin (Ox) in patients with metastatic pancreatic cancer (MPC) J Clin Oncol. 31 4 147 147

66.

EG Chiorean KA Guthrie PA Philip EM Swisher F Jalikis MJ Pishvaian J Berlin MS Noel JM Suga I Garrido-Laguna DB Cardin DL Lew AM Lowy HS Hochster 2019 Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513 J Clin Oncol 37 15 4014 4014

67.

J Bono de RK Ramanathan L Mina 2017 Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers Cancer Discov. 7 6 620 629 https://doi.org/10.1158/2159-8290.CD-16-1250CrossRefPubMedPubMedCentral

68.

KAR Binder R Mick M Ohara U Teitelbaum T Karasic C Schneider PJ Odwyer E Carpenter A Pantel M Makvandi D Mankoff K Nathanson K Maxwell S Cowden MJ Fuhrer J Romeo GL Beatty S Domchek 2019 Abstract CT234: a phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2 Am Assoc Cancer Res. 79 13 234 https://doi.org/10.1158/1538-7445.AM2019-CT234CrossRef

69.

RT Shroff A Hendifar RR McWilliams 2018 Rucaparib monotherapy in patients with pancreatic cancer and a known deleterious BRCA mutation JCO Precis Oncol. https://doi.org/10.1200/PO.17.00316CrossRefPubMedPubMedCentral

70.

AA Turk DA Deming SJ Lubner D Mulkerin NK LoConte A Tevaarwerk KB Wisinski JC Eickhoff G Liu 2018 A phase I study of veliparib (Vel) in combination with oxaliplatin (Ox) and capecitabine (Cap) in advanced solid tumors J Clin Oncol. 36 4 314 314

71.

T Golan GR Varadhachary T Sela DR Fogelman N Halperin RT Shroff S Halparin L Xiao D Aderka A Maitra 2018 Phase II study of olaparib for BRCAness phenotype in pancreatic cancer J Clin Oncol. 36 e297 https://doi.org/10.1200/JCO.2018.36.4_suppl.297CrossRef

72.

J Murai SY Huang A Renaud Y Zhang J Ji S Takeda J Morris B Teicher JH Doroshow Y Pommier 2014 Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib Mol Cancer Ther. 13 2 433 443 https://doi.org/10.1158/1535-7163.MCT-13-0803CrossRefPubMed

73.

MA Lowery DP Kelsen M Capanu SC Smith JW Lee ZK Stadler MJ Moore HL Kindler T Golan A Segal H Maynard E Hollywood M Moynahan EE Salo-Mullen RKG Do AP Chen KH Yu LH Tang EM Oreilly 2018 Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma Eur J Cancer. 89 19 26 https://doi.org/10.1016/j.ejca.2017.11.004CrossRefPubMed

74.

D Melisi V Ossovskaya C Zhu R Rosa J Ling PM Dougherty BM Sherman JL Abbruzzese PJ Chiao 2009 Oral poly(ADP-Ribose) polymerase-1 Inhibitor BSI-401 has antitumor activity and synergizes with oxaliplatin against pancreatic cancer Prevent Acute Neurot Clin Cancer Res. 15 6367 6377 https://doi.org/10.1158/1078-0432.CCR-09-0910CrossRef

75.

KC Strickland BE Howitt SA Shukla S Rodig LL Ritterhouse JF Liu JE Garber D Chowdhury CJ Wu AD D’Andrea 2016 Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer Oncotarget 7 13587 13598 https://doi.org/10.18632/oncotarget.7277CrossRefPubMedPubMedCentral

76.

EE Parkes SM Walker LE Taggart N McCabe LA Knight R Wilkinson KD McCloskey NE Buckley KI Savage M Salto-Tellez 2017 Activation of STING-dependent innate immune signaling By S-phase-specific DNA damage in breast cancer J Natl Cancer Inst. https://doi.org/10.1093/jnci/djw199CrossRefPubMed

77.

EK Lee PA Konstantinopoulos 2019 Combined PARP and immune checkpoint inhibition in ovarian cancer Trends Cancer 5 9 524 528PubMed

78.

S Vinayak SM Tolaney LS Schwartzberg MM Mita GA-L McCann AR Tan AEW Hendrickson A Forero-Torres CK Anders GM Wulf 2018 TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial J Clin Oncol. 36 e1011 https://doi.org/10.1200/JCO.2018.36.15_suppl.1011CrossRef

79.

C Sun Y Fang J Yin J Chen Z Ju D Zhang X Chen CP Vellano KJ Jeong PK Ng 2017 Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers Sci Transl Med. 9 l5148 https://doi.org/10.1126/scitranslmed.aal5148CrossRef

80.

J Ledermann P Harter C Gourley M Friedlander I Vergote G Rustin 2014 Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial Lancet Oncol. 15 852 861PubMed

81.

CC Gunderson KN Moore 2015 BRACAnalysis CDx as a companion diagnostic tool for Lynparza Expert Rev Mol Diagn. 15 1111 1116PubMed

82.

CE Redon AJ Nakamura YW Zhang JJ Ji WM Bonner RJ Kinders 2010 Histone gammaH2AX and poly (ADP-ribose) as clinical pharmacodynamic biomarkers Clin Cancer Res. 16 4532 4542PubMedPubMedCentral

83.

A Mukhopadhyay A Elattar A Cerbinskaite SJ Wilkinson Y Drew S Kyle 2010 Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly (ADP-ribose) polymerase inhibitors Clin Cancer Res. 16 2344 2351PubMed

84.

I Faraoni M Compagnone S Lavorgna DF Angelini MT Cencioni E Piras 1852 BRCA1, PARP1 and gammaH2AX in acute myeloid leukemia: role as biomarkers of response to the PARP inhibitor olaparib Biochim Biophys Acta. 2015 462 472

85.

A Hoglund K Stromvall Y Li LP Forshell JA Nilsson 2011 Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition Cell Cycle 10 3598 3607PubMedPubMedCentral

86.

YH Ibrahim C Garcia-Garcia V Serra L He K Torres-Lockhart A Prat 2012 PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition Cancer Discov. 2 1036 1047PubMedPubMedCentral

87.

CJ Lord A Ashworth 2013 Mechanisms of resistance to therapies targeting BRCA-mutant cancers Nat Med. 19 1381 1388PubMed

88.

C Bolin MT Boudra M Fernet L Vaslin V Pennaneach T Zaremba 2012 The impact of cyclin-dependent kinase 5 depletion on poly (ADP-ribose) polymerase activity and responses to radiation Cell Mol Life Sci. 69 951 962PubMed

89.

CH Lin CY Chang KR Lee HJ Lin TH Chen L Wan 2015 Flavones inhibit breast cancer proliferation through the Akt/FOXO3a signaling pathway BMC Cancer 15 958PubMedPubMedCentral

Titel: PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer
verfasst von: Devashish Desai
Pushti Khandwala
Meghana Parsi
Rashmika Potdar
Publikationsdatum: 01.06.2021
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 6/2021
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-021-01507-9

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2021

Luteolin and cancer metastasis suppression: focus on the role of epithelial to mesenchymal transition

CDK2-instigates C/EBPα degradation through SKP2 in Acute myeloid leukemia

Identification of hub genes associated with obesity-induced hepatocellular carcinoma risk based on integrated bioinformatics analysis

H2O2 enhances the anticancer activity of TMPyP4 by ROS-mediated mitochondrial dysfunction and DNA damage

Upfront metastasis-directed therapy in oligorecurrent prostate cancer does not decrease the time from initiation of androgen deprivation therapy to castration resistance

The effect of the COVID-19 pandemic on routine adult vaccination in cancer patients

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie